Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
OND denies Acer’s appeal but describes possible paths forward for EDSIVO™ACER-001 bioequivalence trial complete; New Drug Application submission anticipated early […]